BKBeate Krämer

Beate Krämer

*This is an algorithmically generated author record based on publicly available information.

Beate Krämer has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Validation of the “BINACLE” (binding and cleavage) assay for the in vitro safety testing of tetanus vaccines

    by Heike A. Behrensdorf-Nicol, Jolanta Klimek, Ursula Bonifas, Kay-Martin Hanschmann, Beate Krämer

  • Open Access

    Quantification of Lyssavirus-Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudotype Particles

    by Sarah Moeschler, Samira Locher, Karl-Klaus Conzelmann, Beate Krämer, Gert Zimmer

    Rabies is a highly fatal zoonotic disease which is primarily caused by rabies virus (RABV) although other members of the genus Lyssavirus can cause rabies as well. As yet, 14 serologically and genetically diverse lyssaviruses have been identified, mostly in bats. To assess the quality of rabies vaccines and immunoglobulin preparations, virus neutralization tests with live RABV are performed in accordance with enhanced biosafety standards. In the present work, a novel neutralization test is presented which takes advantage of a modified vesicular stomatitis virus (VSV) from which the glycoprotein G gene has been deleted and replaced by reporter genes. This single-cycle virus was trans-complemented with RABV envelope glycoprotein. Neutralization of this pseudotype virus with RABV reference serum or immune sera from vaccinated mice showed a strong correlation with the rapid fluorescent focus inhibition test (RFFIT). Importantly, pseudotype viruses containing the envelope glycoproteins of other lyssaviruses were neutralized by reference serum to a significantly lesser extent or were not neutralized at all. Taken together, a pseudotype virus system has been successfully developed which allows the safe, fast, and sensitive detection of neutralizing antibodies directed against different lyssaviruses.


  • Reduktion von Tierversuchen in der experimentellen Arzneimittelprüfung

    by H. Behrensdorf-Nicol, B. Krämer

    In order to ensure the quality of biomedical products, an experimental test for every single manufactured batch is required for many products. Especially in vaccine testing, animal experiments are traditionally used for this purpose. For example, efficacy is often determined via challenge experiments in laboratory animals. Safety tests of vaccine batches are also mostly performed using laboratory animals. However, many animal experiments have clear inherent disadvantages (low accuracy, questionable transferability to humans, unclear significance). Furthermore, for ethical reasons and animal welfare aspects animal experiments are also seen very critical by the public. Therefore, there is a strong trend towards replacing animal experiments with methods in which no animals are used ("replacement"). If a replacement is not possible, the required animal experiments should be improved in order to minimize the number of animals necessary ("reduction") and to reduce pain and suffering caused by the experiment to a minimum ("refinement"). This "3R concept" is meanwhile firmly established in legislature. In recent years many mandatory animal experiments have been replaced by alternative in vitro methods or improved according to the 3R principles; numerous alternative methods are currently under development. Nevertheless, the process from the development of a new method to its legal implementation takes a long time. Therefore, supplementary regulatory measures to facilitate validation and acceptance of new alternative methods could contribute to a faster and more consequent implementation of the 3R concept in the testing of biomedical products.


  • A multi-dose serological assay suitable to quantify the potency of inactivated rabies vaccines for veterinary use

    by Beate Krämer, Elisabeth Kamphuis, Kay-Martin Hanschmann, Catherine Milne, Arnold Daas, Karin Duchow


    • 1 January 1998
      • Vol. 15  (5) , 43-45

    [Detection of extraneous virus in live vaccines]

    by Beate Krämer, Petra Rübmann, Karin Cubetaler Klaus Duchow

    In the study in vitro alternatives to a non-validated and harmful animal test for the absence of extraneous virus in live vaccines were investigated. For evaluation of a suitable in vitro method the porcine herpesvirus (Aujeszkyvirus, Pseudorabiesvirus) was used as a model virus. In artificially contaminated live vaccines the aujeszkyvirus could be detected by moleculargenetical and cellular methods. Regarding the threshold values of virus detection in vitro tests showed to be more efficacious than animal testing. Meanwhile the European Pharmacopoeia Commission deleted the animal test for extraneous virus from two monographs. The discussion, if respective animal testing can be cancelled for the other live vaccines as well, is still ongoing. The study was supported by the German Ministry of Education, Science, Research and Technology.

    • 1 January 1998
      • Vol. 15  (5) , 46-49

    [How to prove complete virus inactivation in rabies vaccines. A comparison of an in vivo to an in vitro method]

    by Stephanie A. E. Blum, Manuela Braunschweiger, Beate Krämer, Petra Rübmann, Karin Duchow, Klaus Cubetaler

    At present, the complete inactivation of rabies virus in rabies vaccines ad us. vet. is proven by an animal experiment which causes severe suffering, the intracerebral injection of mice. This animal experiment yet is not validated. We have quantified the sensitivity of the mouse test and examined whether the animal experiment may be replaced by the immunofluorescence assay (IFT) as an in vitro method. Detection limits of both assays were determined depending on the examined product, i.e. prior to and after the addition of adjuvans and preservative, respectively. Furthermore, symptoms of the rabies desease were recorded and their severity was classified on a range of 1-5. Symptoms of rabies-infected mice were clear and highly specific. Symptoms classified as >/= 2 in context with a loss of >/= 15% of the initial weight were defined as humane endpoints of the desease. The quantitative detection of active virus was not inhibited in the presence of even high concentrations of inactivated virus. The detection limit of the mouse test was 10 viruses ml-1 independent of the examined product. The detection limit of the IFT prior to the addition of adjuvans and preservative was 10 viruses ml-1 as well. After the addition of these substances the detection limit rose to 103 viruses ml-1. Advantages and disadvantages of the mouse test and IFT are discussed.


    • 1 January 1996
      • Vol. 13  (1) , 7-16

    [Is the abnormal toxicity test still relevant for the safety of vaccines, sera and immunoglobulins?]

    by Beate Krämer, Margit Nagel, Karin Duchow, Michael Schwanig, Klaus Cussler

    The German Pharmacopoeia (DAB) requires the abnormal toxicity test (ATT) using mice and guinea pigs as a non-specific safety test for vaccines, sera and immuno-globulines. The purpose of this project was to investigate the relevance of ATT after the introduction of GMP- and GLP-principles in the manufacturing of biological products. A great variability in the test performance became evident for the different test laboratories, involving the animal number as well as the vaccine dosage administration and test duration. The retrospective analysis of ATT results reveals reasons for the incompatibility of particular preparation groups, vaccine components or additives with the animal species used. There were highly significant differences between the manufacturers and the PEI regarding the frequency of deviating test results for identical test batches. Positive ATT"s never resulted from the insufficient quality of a batch. On the other hand vaccines causing adverse reactions in the target species were not identified by the ATT. For these reasons the abnormal toxicity test is unsuitable to detect harmful batches. The results of the analysis of data show that finally the ATT has always been passed, i.e. there was no retention by the vaccine manufacturers and no refusal by the controlling authorities due to the ATT-results. Considering the present animal model and the questionable transferability of the test results to the target species only a poor reliability is evident. Taking into account aspects of drug safety and animal welfare it is recommended to the DAB to omit the ATT.